Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type (Allogeneic, Autologous); Product (Consumables, Equipment, Systems and Software); Technology (Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, Three-dimensional Technology); Application (Oncology, Cardiovascular, Orthopedic, Wound Management, Other Applications); End User (Research Institutes, Hospitals, Others), and Geography
Publication Month: Jan 2021 | Report Code: TIPRE00009666 | No. of Pages: 201 | Category: Biotechnology | Status: Published
The cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. The market is estimated to grow at a CAGR of 7.2% from 2020–2027.
The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the cell therapy market
Lucrative Regions for Cell Therapy Market
Get more information on this report :
Market Insights
Increasing Number of Approvals for Cell-Based Therapies
The advancements in biotechnology have led to the adoption of personalized treatments for a wide range of indications. Stem cell therapies are being used to treat chronic diseases, such as cancer, neurological disorders, and genetic disorders. Further, the advantages of cell therapy such as targeted treatment, faster and efficient recovery, and reduced side effects promote the adoption of various products. In North America, cell therapies are widely adopted owing to the availability of FDA-approved products. For instance, in April 2020, the FDA awarded regenerative medicine advanced therapy designation to Novartis' Kymriah to treat refractory (r/r) follicular lymphoma (FL) in adults. In July 2020, the FDA approved a CAR T-cell therapy brexucabtagene autoleucel (Tecartus) for patients with mantle cell lymphoma. It is the first FDA-approved CAR T-cell therapy for mantle cell lymphoma and it was approved under the Accelerated Approval pathway. Tecartus also received Orphan Drug designation, which encourages the development of drugs for rare diseases. The other approved CAR-T cell therapies for cancer are Kymriah for acute lymphoblastic leukemia and Yescarta for diffuse large B-cell lymphoma. Apart from this, with more than 250 clinical trials worldwide studying CAR T-cell therapies, additional cell therapies are on their way with potential indications including pancreatic cancer, autoimmune diseases, Alzheimer’s, and Parkinson’s disease. This is expected to drive the cell therapy market.
Therapy Type-Based Insights
The cell therapy market, based on therapy type, is bifurcated into allogeneic and autologous. In 2019, the allogeneic segment accounted for a larger share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe.
Cell Therapy Market, by Therapy Type – 2019 and 2027
Get more information on this report :
Product-Based Insights
The cell therapy market, by product, is segmented into consumables, equipment, and systems and software. The consumables segment held the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR in the market during the forecast period.
Technology-Based Insights
Based on technology, the cell therapy market is segmented into viral vector technology, genome editing technology, somatic cell technology, cell immortalization technology, cell plasticity technology, and three-dimensional technology. The viral vector technology segment held the largest share of the market in 2019. Also, the same segment is anticipated to register the highest CAGR in the market during 2020–2027.
Application-Based Insights
The cell therapy market, by application, is segmented into oncology, cardiovascular, orthopedic, wound management, and other applications. The oncology segment held the largest share of the market in 2019. Also, the same segment is anticipated to register the highest CAGR in the market during the forecast period.
End User-Based Insights
Based on end user, the cell therapy market is segmented into hospitals, research institutes, and others. The research institutes segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR in the market during the forecast period.
Strategic Insights
A few players operating in the cell therapy market are Vericel Corporation; MEDIPOST; NuVasive, Inc.; Mesoblast Limited; JCR Pharmaceuticals Co. Ltd.; Smith & Nephew; Bristol-Myers Squibb Company; Cells for Cells; Stemedica Cell Technologies, Inc; and Castle Creek Biosciences, Inc. These players are adopting several organic and inorganic strategies to enhance their revenue and market standings. For instance, in November 2019, MEDIPOST started the extension of its GMP manufacturing facility. The facility is anticipated to increase the sales of CARTISTEM and the development of a new pipeline of products.
Cell Therapy Market– by Therapy Type
- Allogeneic
- Autologous
Cell Therapy Market– by Product
- Consumables
- Equipment
- Systems and Software
Cell Therapy Market– by Technology
- Viral Vector Technology
- Genome Editing Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Cell Plasticity Technology
- Three-Dimensional Technology
Cell Therapy Market– by Application
- Oncology
- Cardiovascular
- Orthopedic
- Wound Management
- Other Applications
Cell Therapy Market– by End User
- Research Institutes
- Hospitals
- Others
Cell Therapy Market – by Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
South and Central America
- Brazil
- Argentina
Company Profiles
- Vericel Corporation
- MEDIPOST
- NuVasive, Inc.
- Mesoblast Limited
- JCR Pharmaceuticals Co. Ltd.
- Smith & Nephew
- Bristol-Myers Squibb Company
- Cells for Cells
- Stemedica Cell Technologies, Inc,
- Castle Creek Biosciences, Inc.
Frequently Asked Questions
The List of Companies - Cell Therapy Market
- Vericel Corporation
- MEDIPOST
- NuVasive, Inc.
- Mesoblast Limited
- JCR Pharmaceuticals Co. Ltd.
- Smith & Nephew
- Bristol-Myers Squibb Company
- Cells for Cells
- Stemedica Cell Technologies, Inc,
- Castle Creek Biosciences, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the cell therapy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Get the Latest COVID-19 Analysis on this market
Have a Question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
-
$3000 $2700
$4550 $4095$6550 $5568$8550 $6840Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount
